More answers like this
GPT-5Oct 24, 2026openai/gpt-5-2025-08-07
Should AI development be paused or restricted?
Short answer: Some AI development should be paused or restricted, but in a targeted, trigger-based way—not a blanket freeze. Think “smart brakes” that engage when risk is high, while keeping safe, beneficial work moving.
When a pause makes sense
•Clear red flags in evaluations: models demonstrate capabilities that materially raise biosecurity, cyber‑offense, or autonomous replication risks, and mitigations are not yet reliable.
•Unresolved safety incidents: near-misses or harm that reveal systemic gaps in containment, monitoring, or abuse prevention.
•Missing safety case: the developer can’t produce a credible, independently reviewed pre‑deployment safety case for a high‑capability model.
•Sharp capability jumps: training runs far beyond prior scales without commensurate safety controls; call a time‑boxed moratorium to evaluate.
What to restrict now (capability- and context-based)
•High‑risk assistance: actionable bio/chem design, exploit generation, critical‑infrastructure interference, targeted disinformation, or instructions enabling violent wrongdoing.
•Autonomy with real-world leverage: agents that can spend money, write/execute code, control tools/robots, or self‑replicate—require strong gating, human oversight, and rollback.
•Fine‑tuning and tool coupling: restrict public fine‑tuning or plug‑ins that significantly boost risky capabilities unless providers meet higher assurance standards.
•Access controls: identity/KYC for powerful endpoints, rate limits, abuse detection, and graduated access based on verified need.
Governance mechanisms that balance safety and progress
•Licensing for frontier training above defined compute/energy thresholds, tied to safety requirements, cyber/security standards, and incident reporting.
•Pre‑deployment safety cases: red‑teaming against agreed threat models, external audits, and documented mitigations; do not ship until pass criteria are met.
•Independent evaluations: standardized, third‑party capability/risk testing with transparent metrics and reproducible protocols.
•Compute governance: reporting of very large training runs to an appropriate regulator; secure data centers with tamper‑evident logging.
•Model weight security: strong internal controls; if weights are released, ensure they’re safety‑hardened and decoupled from dangerous toolchains.
•Responsible release: staged rollouts, kill‑switches, and continuous post‑deployment monitoring; pause/rollback triggers pre‑defined.
•Content provenance: watermarking or authenticated media (e.g., C2PA) to help downstream platforms moderate harms.
Open-source considerations
•Allow open base models for research/innovation, but restrict distribution or coupling that turns them into turnkey bio/cyber weapons.
•Encourage “safety by default” (usage policies, filtered training data, red‑team reports) and responsible distribution norms.
•Provide controlled research access to evaluate and improve defenses without broadly enabling misuse.
Protecting innovation, competition, and rights
•Use risk tiers: minimal rules for low‑risk applications; heavier obligations only for demonstrably high‑risk systems.
•Sunset clauses and periodic review so restrictions don’t ossify or entrench incumbents.
•Due process and transparency for regulatory decisions; preserve security research and whistleblower protections.
International coordination
•Align on minimum safety standards and incident-sharing across countries; coordinate export controls for the highest‑end chips and training clusters to reduce proliferation risks.
•Support capacity‑building so smaller labs can meet safety baselines without exiting the field.
A practical decision checklist
•Capability: Does the model cross agreed thresholds in bio/cyber/autonomy?
•Exposure: Will it be broadly accessible or tool‑augmented?
•Mitigations: Are defenses effective under adversarial testing?
•Governance: Have audit, reporting, and rollback plans been validated by independents?
•Residual risk: If high and poorly bounded, institute a time‑boxed pause; if moderate and bounded, proceed with restrictions and monitoring.
Bottom line: Don’t pause AI across the board. Do impose targeted, enforceable pauses when risk triggers are hit, and maintain strong, capability‑proportionate restrictions and oversight. This approach preserves the upside of AI while keeping credible, high‑impact risks within society’s risk tolerance.